Azenta Appoints Trey Martin as Multiomics President to Scale Gene Synthesis
Azenta appointed Trey Martin as President of its Multiomics business effective April 6, 2026, to accelerate execution of its December 2025 long-range plan focused on scaling global gene synthesis capabilities and driving profitable growth. Ginger Zhou will step down to an advisory role through November 2026 to ensure continuity.
1. Leadership Transition
Azenta named Trey Martin as President of its Multiomics business effective April 6, 2026. He will report to CEO John Marotta and lead the Multiomics organization in executing the company’s long-range plan to scale global gene synthesis capabilities and enhance commercial discipline.
2. Transition and Continuity
Ginger Zhou will step down as President of Multiomics but remain in an advisory capacity through November 2026. This arrangement is designed to ensure a smooth handover and maintain operational continuity as the business advances into its next phase.
3. Executive Background and Strategy
Martin brings over 30 years of life sciences leadership, including serving as CEO of Maravai Life Sciences and senior roles at Danaher and Integrated DNA Technologies. His appointment aligns with Azenta’s strategic priorities to strengthen operational excellence and drive profitable growth across its integrated Multiomics platform.